High molecular weight polysaccharide that binds and inhibits virus
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A01N-043/04
A61K-031/715
출원번호
US-0694226
(2010-01-26)
등록번호
US-8629121
(2014-01-14)
발명자
/ 주소
Konowalchuk, Thomas W.
Konowalchuk, Jack
출원인 / 주소
World Force Technologies, LLC
대리인 / 주소
Haliday, Emily M.
인용정보
피인용 횟수 :
2인용 특허 :
7
초록▼
This invention provides a high molecular weight polysaccharide capable of binding to and inhibiting virus and related pharmaceutical formulations and methods of inhibiting viral infectivity and/or pathogenicity, as well as immunogenic compositions. The invention further includes methods of inhibitin
This invention provides a high molecular weight polysaccharide capable of binding to and inhibiting virus and related pharmaceutical formulations and methods of inhibiting viral infectivity and/or pathogenicity, as well as immunogenic compositions. The invention further includes methods of inhibiting the growth of cancer cells and of ameliorating a symptom of aging. Additionally, the invention provides methods of detecting and/or quantifying and/or isolating viruses.
대표청구항▼
1. A composition that binds to a virus and inhibits said virus, said composition comprising: an isolated polysaccharide comprising an arabinofuranosyl residue, a galactopyranosyl residue, and a galactouronic acid; anda catechin polymer;wherein said composition is soluble in water;wherein said compos
1. A composition that binds to a virus and inhibits said virus, said composition comprising: an isolated polysaccharide comprising an arabinofuranosyl residue, a galactopyranosyl residue, and a galactouronic acid; anda catechin polymer;wherein said composition is soluble in water;wherein said composition provides a NMR spectrum as shown in FIG. 3A; andwherein said composition binds to a virus and reduces the infectivity or pathogenecity of said virus. 2. A composition that binds to a virus and inhibits said virus, said composition comprising: an isolated polysaccharide comprising an arabinofuranosyl residue, a rhamnopyranosyl residue, a galactopyranosyl residue, a glucopyranosyl residue, a mannopyranosyl residue, and a galactouronic acid; anda non-carbohydrate aromatic polymer;wherein said composition comprises about 40 to about 44 percent oxygen, about 44 to about 48 percent carbon, about 3 to about 6 percent hydrogen; and about 0.1 to about 1 percent nitrogen;wherein said composition is soluble in water;wherein said composition provides a NMR spectrum as shown in FIG. 3A; andwherein said composition binds to a virus and reduces the infectivity or pathogenecity of said virus. 3. The composition of claim 1, wherein the composition comprises about 10 to about 30 weight percent polysaccharide and about 70 to about 90 weight percent catechin polymer. 4. The composition of claim 1, wherein the composition comprises a component having a molecular weight greater than about 1 million Daltons. 5. The composition of claim 1, wherein the composition comprises a component having a molecular weight in the range of about 60,000 to about 100,000 Daltons. 6. The composition of claim 4, wherein the composition comprises an additional component having a molecular weight in the range of about 60,000 to about 100,000 Daltons. 7. The composition of claim 6, wherein the ratio of the amount of the component having a molecular weight greater than about 1 million Daltons to the amount of the component having a molecular weight in the range of about 60,000 to about 100,000 Daltons is about 95:5. 8. The composition of claim 1, wherein said composition does not comprise protein. 9. The composition of claim 1, wherein said polysaccharide comprises: about 30 to about 75 mole percent arabinose;about 0 to about 10 mole percent rhamnose;about 0 to about 5 mole percent xylose;about 0 to about 8 mole percent glucuronic acid;about 3 to about 36 mole percent galactouronic acid;about 0 to about 6 mole percent mannose;about 1 to about 20 mole percent galactose; andabout 0 to about 13 mole percent glucose. 10. The composition of claim 2, wherein said polysaccharide comprises: about 60 to about 66 mole percent arabinose;about 4.1 to about 4.5 mole percent rhamnose;about 2.2 to about 2.4 mole percent xylose;about 8.7 to about 9.7 mole percent galactouronic acid;about 2.3 to about 2.5 mole percent mannose;about 13.7 to about 15.1 mole percent galactose; andabout 4.2 to about 4.6 mole percent glucose. 11. The composition of claim 1, wherein said composition binds a virus from a family selected from the group consisting of Adenoviridae, Picornaviridae, Reoviridae, Arenaviridae, Bunyaviridae, Coroanviridae, Herpesviridae, Orthomyxoviridae, Paramyxoviridae, Poxviridae Rhabdoviridae, Flaviviridae, and Retroviridae. 12. The composition of claims 1 or 2, wherein said composition is formulated in a pharmaceutically acceptable excipient. 13. The composition of claim 12, wherein said composition is formulatec as a unit dosage formulation. 14. The composition of claim 12, wherein said composition is formulated in a delivery form selected from the group consisting of a tablet, a capsule, a lozenge, an ointment, a cream, a transdermal formulation (e.g., a patch), a gel, a nasal spray, a suppository, an injectable, and an implantable sustained-release formulation. 15. A method of preparing the composition of claims 1 or 2, said method comprising: preparing a substantially homogeneous aqueous mixture or solution of plant material from one or more plants of the Vitaceae family;contacting said mixture with an ion exchange resin and recovering the colored product; andfurther purifying the colored product by removing components that can pass through a dialysis filter that generally passes molecules having a molecular weight of a 5×105 Daltons or less to produce a composition that binds a virus. 16. A method of inhibiting the infectivity and/or pathogenicity of a virus, said method comprising contacting said virus with a composition according to claims 1 or 2. 17. A method of inhibiting the growth and/or proliferation of a cancer cell, said method comprising contacting said cancer cell with a composition according to claims 1 or 2. 18. An immunogenic composition, said composition comprising a composition according to claims 1 or 2 bound to a virus. 19. A method of inducing an immune response in a mammal, said method comprising administering to said mammal an immunogenic composition according to claim 18 in an amount sufficient to induce an immune response. 20. A method of ameliorating a symptom of aging in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition according to claim 1, wherein said effective amount is sufficient to ameliorate a least one symptom of aging. 21. A method of detecting and/or quantifying a virus, said method comprising: contacting a sample with a polysaccharide composition according to claim 1, under conditions suitable for the polysaccharide composition to bind any virus present in the sample; anddetecting and/or quantifying binding to said polysaccharide composition. 22. A device comprising a solid support having attached thereto a polysaccharide composition according to claim 1. 23. A method of isolating one or more viruses from a sample, the method comprising: (a) contacting the sample with a polysaccharide composition according to claim 1 that is affixed to a substrate under conditions suitable for the polysaccharide composition to bind any virus present in the sample; and(b) washing the substrate to remove unbound sample material.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (7)
Umezawa Iwao (Tokyo JPX) Komiyama Kanki (Kanagawa JPX), Acidic polysaccharide CH-1 isolated from Chlorella pyrenoidosa and the use thereof.
Phalipon, Armelle; Sansonetti, Philippe; Felici, Franco; Cortese, Riccardo; Kraehenbuhl, Jean Pierre, Immunogenic polypeptides that mimic a surface polysaccharide antigen of a pathogenic microorganism, method for obtaining the same, and their use in vaccine compositions.
Masquelier Jack (Parc des Tourelles FRX), Plant extract with a proanthocyanidins content as therapeutic agent having radical scavenger effect and use thereof.
Frangi Enrico (Milan ITX) Bertani Marco (Milan ITX) Mustich Giuseppe (Milan ITX) Tuccini Gianfranco (Milan ITX), Process for preparing grapeseed extracts enriched in procyanidol oligomers.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.